FDA could add a more visual symbol of its approval of REMS materials and communications in order to entice more providers to read them, members of the agency’s Risk Communication Advisory Committee suggested Dec. 17.
FDA is looking to improve Risk Evaluation and Mitigation Strategies’ impact among providers, including better efforts to ensure that “Dear Healthcare Provider” letters and other information about new or changed
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?